The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding a hearing on the case of administrative dispute over the invalidity of invention patent between the appellant Boehringer Ingelheim and the appellee China National Intellectual Property Administration (CNIPA), as well as third parties of first instance Hansoh Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., CTTQ Pharma, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., and Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.
Patent Dispute Background
BI sued CNIPA and the Chinese companies due to a patent dispute concerning Jardiance (empagliflozin), an SGLT2 inhibitor co-developed by Eli Lilly and approved in the US and China in 2014 and 2017 respectively. A slew of domestic companies, including those mentioned above, have challenged the drug’s patent since, with CNIPA declaring all patents of empagliflozin invalid in September 2020.-Fineline Info & Tech
Leave a Reply